As a Free StocksGuide user, you can view scores for all 7,027 stocks worldwide.
18 Analysts have issued a Voyager Therapeutics, Inc. forecast:
18 Analysts have issued a Voyager Therapeutics, Inc. forecast:
Jun '25 |
+/-
%
|
||
Revenue | 43 43 |
70%
70%
|
|
Gross Profit | - - |
-
|
|
EBITDA | -119 -119 |
12,261%
12,261%
|
EBIT (Operating Income) EBIT | -123 -123 |
3,109%
3,109%
|
Net Profit | -108 -108 |
1,297%
1,297%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
Voyager Therapeutics, Inc. operates as a clinical-stage gene therapy company, which develops treatments for patients suffering from central nervous system. Its pipeline of gene therapy programs includes VY-AADC, VY-SOD101, VY-HTT01, VY-FXN01, Tau Program, and VY-NAV01. The company was founded by Guangping Gao, Mark A. Kay, Krystof Bankiewicz and Phillip Zamore in June 2013 and is headquartered in Cambridge, MA.
Head office | United States |
CEO | Alfred Sandrock |
Employees | 172 |
Founded | 2013 |
Website | www.voyagertherapeutics.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.